Sign in
IMVT Stock Price, Chart, Stats & News
Immunovant, Inc.
Save
7.26B
Market cap
–
Current P/E
–
Forward P/E
IMVT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.79% |
ROA | -44.11% |
ROE | -65.80% |
D/E | – |
Interest coverage ratio | – |
IMVT valuation
P/E | – |
P/S | – |
P/B | 4.41x |
P/CF | -10.29x |
P/FCF | -11.54x |
P/OCF | -10.29x |
PEG | -1.78x |
EV multiple | -12.20x |
About
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Similar securities
Based on sector and market capitalization
Report issue